ORPHAN SYNERGY EUROPE-PHARMA (EPA:OSE) | Finanzwire

Basculer en Français

10230	Companies
211156	Keywords
141075	Articles
111857	Press releases

Headlines Articles Press releases ORPHAN SYNERGY EUROPE-PHARMA

Home
Companies
ORPHAN SYNERGY EUROPE-PHARMA

BRIEF

published on 04/15/2026 at 07:35, 1 day 21 hours ago

OSE Immunotherapeutics presents a novel antibody at the AAI Congress 2026

OSE Immunotherapeutics Monoclonal Antibody FPR2 Chronic Inflammation AAI Congress 2026
PRESS RELEASE

published on 04/15/2026 at 07:30, 1 day 21 hours ago

OSE Immunotherapeutics to Present a Novel, First-in-Class, FPR2 Agonist Monoclonal Antibody in the Resolution of Chronic Inflammation at the AAI 2026 Meeting
OSE Immunotherapeutics to present a novel FPR2 agonist monoclonal antibody aiming to resolve chronic inflammation at the AAI 2026 Meeting in Boston

OSE Immunotherapeutics Monoclonal Antibody FPR2 Chronic Inflammation Agonist
BRIEF

published on 03/16/2026 at 07:35, 1 month ago

OSE Immunotherapeutics Unveils 2026 Financial Calendar

Annual General Meeting Investor Relations Financial Calendar Biotech Industry OSE Immunotherapeutics
BRIEF

published on 03/16/2026 at 07:35, 1 month ago

OSE Immunotherapeutics unveils its financial calendar for 2026

Treasury Financial Calendar General Assembly OSE Immunotherapeutics 2026 Financial Results
PRESS RELEASE

published on 03/16/2026 at 07:30, 1 month ago

OSE Immunotherapeutics Announces its 2026 Financial Calendar
OSE Immunotherapeutics announces its 2026 financial calendar, including key dates for financial updates and statements, and annual general meeting

Annual General Meeting Financial Updates Biotech Company OSE Immunotherapeutics 2026 Financial Calendar
BRIEF

published on 01/21/2026 at 18:05, 2 months 26 days ago

FDA Grants Orphan Drug Status to OSE Immunotherapeutics' Pegrizeprument

OSE Immunotherapeutics FDA Orphan Drug Pegrizeprument Organ Transplantation Veloxis Pharmaceuticals
PRESS RELEASE

published on 01/21/2026 at 18:00, 2 months 26 days ago

OSE Immunotherapeutics Welcomes FDA Orphan Drug Designation Granted to Pegrizeprument (VEL-101)
OSE Immunotherapeutics acknowledges FDA Orphan Drug Designation granted to pegrizeprument (VEL-101) for organ rejection prevention in liver transplant patients. Veloxis Pharmaceuticals to develop and commercialize the product globally

FDA Orphan Drug Designation OSE Immunotherapeutics Pegrizeprument VEL-101
BRIEF

published on 12/09/2025 at 07:35, 4 months 7 days ago

OSE Immunotherapeutics' new strategic plan for 2026-2028

Strategic Plan Funding OSE Immunotherapeutics Lusvertikimab Tedopi® Phase 3
BRIEF

published on 12/09/2025 at 07:35, 4 months 7 days ago

OSE Immunotherapeutics Announces Strategic Plan for 2026–2028

Strategic Plan Financial Strategy Scientific Leadership Tedopi Trial Lusvertikimab Development
PRESS RELEASE

published on 12/09/2025 at 07:30, 4 months 7 days ago

OSE Immunotherapeutics Unveils 2026–2028 Strategic Plan With Four Opportunities for Value Creation
OSE Immunotherapeutics unveils 2026–2028 strategic plan focusing on Tedopi's phase 3, rare indications for Lusvertikimab, subcutaneous formulation in UC, and maintaining scientific leadership

Strategic Plan Scientific Leadership OSE Immunotherapeutics Tedopi Phase 3 Lusvertikimab Indications

1 2 ... 5

Accesswire

Published on 04/17/2026 at 02:13, 2 hours 27 minutes ago

CHAR Tech annonce l’acquisition projetée d’actifs de biocarbone au Québec, incluant un accord d’achat de 62 500 tonnes, une installation et de la propriété intellectuelle
Published on 04/17/2026 at 02:00, 2 hours 40 minutes ago

UraniumX Announces Closing Of Final Tranche Of Non-Brokered Private Placement
Published on 04/16/2026 at 23:32, 5 hours 8 minutes ago

Zomedica Announces “Fourth Friday at Four” Webinar on April 24th: A Behind-the-Scenes Look at Manufacturing Excellence and Operational Scale
Published on 04/16/2026 at 21:30, 7 hours 10 minutes ago

Organto Foods Expands Financing Facilities with Rabobank
Published on 04/16/2026 at 15:55, 12 hours 45 minutes ago

TripSitter Announces Director Resignation

View all ACCESSWIRE

EQS Group

Published on 04/16/2026 at 23:40, 5 hours ago

Coventry Ranks #1 in 2025 Life Settlement League Table Report
Published on 04/16/2026 at 21:37, 7 hours 3 minutes ago

Approval of the Offer Document concerning the voluntary tender offer for shares of NEXT RE SIIQ S.p.A.
Published on 04/16/2026 at 21:00, 7 hours 40 minutes ago

Vizrt AI Keyer kills the green screen and creates virtual scenes in any environment
Published on 04/16/2026 at 20:35, 8 hours 5 minutes ago

EQS-Adhoc: Correction of a release from 16/04/2026, 19:17 CET/CEST - Drägerwerk AG & Co. KGaA: Preliminary figures Q1 2026: Earnings significantly above prior year
Published on 04/16/2026 at 19:17, 9 hours 22 minutes ago

EQS-Adhoc: Drägerwerk AG & Co. KGaA: Preliminary figures Q1 2026: Earnings significantly above prior year

Les Echos

Published on 04/16/2026 at 18:02, 10 hours 38 minutes ago

Covivio - Description of the share buy-back program authorized by the Combined Ordinary and Extraordinary Shareholders’ Meeting held on 16 April 2026
Published on 04/16/2026 at 18:00, 10 hours 40 minutes ago

ICADE – PR – Q1 2026 TRADING UPDATE
Published on 04/16/2026 at 17:55, 10 hours 45 minutes ago

Publication of 2026 1st quarter turnover
Published on 04/16/2026 at 17:54, 10 hours 46 minutes ago

Aéroports de Paris S.A - March 2026 traffic figures
Published on 04/16/2026 at 17:45, 10 hours 55 minutes ago

VOGO : 2025 full-year results.

View all LES ECHOS COMFI WIRE